Recent investigations have centered on the overlap of GLP|GIP|GCGR activator therapies and DA neurotransmission. While GLP agonists are increasingly employed for managing type 2 diabetes mellitus, their unexpected https://keziactgf602845.liberty-blog.com/41297034/emerging-glp-agonists-and-dopaminergic-modulation-a-comparative-copyrightination